23andMe, a company known for DNA testing, is facing challenges as mass-market genetic testing is found to have limited benefits for most people. The company's focus on genetic differences is questioned, with critics highlighting the lack of significant impact. Despite having data from 15 million users, 23andMe is struggling and risks being delisted from Nasdaq.
Shares of this gene editing company are due to surge more than 45%, Citi says https://t.co/jPOuPGod61
In #SyntheticBiology news, BTIG on Wednesday downgraded shares of Ginkgo Bioworks to a Sell rating with a price target of $0.50. Ginkgo $DNA shares were at $14 during the 2021 #biotech boom, but they've been trading as a penny stock for a while now. https://t.co/6uylPsznsH https://t.co/AE7XwIVyiB
23andMe, on verge of being delisted from Nasdaq, is still waiting for a revolution in debugging our DNA. Its greatest asset is data from 15 million users it mines for potential drugs. (Though they haven't told me why I have clumpy platelets) https://t.co/cY8gGnze0z @BW
The chief product of home DNA tests may be awkward family conversations https://t.co/C2zjoQyh9c via @BW
About a decade ago we were told the answers to our greatest questions could be ours if we spat in a tube. However, mass-market genetic testing has little to offer most people. @kristenvbrown explains https://t.co/KM4KvJgJ1H https://t.co/JyB3a5ZGeX
23andMe’s rapid downfall shows DNA testing has limited benefits https://t.co/OWvJHqK3M1 Me: “It seems almost absurd that we’re focusing on these slight genetic differences between individuals & suggesting that’s going to make a significant change.” @jamestabery: "Everyone now…
Mass-market genetic testing has little to offer most people. That’s a big problem for 23andMe. https://t.co/zlw1iKe9QW $me
23andMe’s rapid downfall shows DNA testing has limited benefits https://t.co/yrYyN0C10x